These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21946335)

  • 1. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease.
    Franciosi S; Ryu JK; Shim Y; Hill A; Connolly C; Hayden MR; McLarnon JG; Leavitt BR
    Neurobiol Dis; 2012 Jan; 45(1):438-49. PubMed ID: 21946335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated deformation analysis in the YAC128 Huntington disease mouse model.
    Lerch JP; Carroll JB; Spring S; Bertram LN; Schwab C; Hayden MR; Henkelman RM
    Neuroimage; 2008 Jan; 39(1):32-9. PubMed ID: 17942324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin.
    Connolly C; Magnusson-Lind A; Lu G; Wagner PK; Southwell AL; Hayden MR; Björkqvist M; Leavitt BR
    Neuroscience; 2016 Jun; 325():74-88. PubMed ID: 27033979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YAC128 mouse model of Huntington disease is protected against subtle chronic manganese (Mn)-induced behavioral and neuropathological changes.
    Wilcox JM; Pfalzer AC; Tienda AA; Debbiche IF; Cox EC; Totten MS; Erikson KM; Harrison FE; Bowman AB
    Neurotoxicology; 2021 Dec; 87():94-105. PubMed ID: 34543681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease.
    Garcia-Miralles M; Yusof NABM; Tan JY; Radulescu CI; Sidik H; Tan LJ; Belinson H; Zach N; Hayden MR; Pouladi MA
    Mol Neurobiol; 2019 Jun; 56(6):4464-4478. PubMed ID: 30334188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
    Tang TS; Chen X; Liu J; Bezprozvanny I
    J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microglia density decreases with age in a mouse model of Huntington's disease.
    Ma L; Morton AJ; Nicholson LF
    Glia; 2003 Sep; 43(3):274-80. PubMed ID: 12898706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
    Mazarei G; Budac DP; Lu G; Adomat H; Tomlinson Guns ES; Möller T; Leavitt BR
    J Neurochem; 2013 Dec; 127(6):852-67. PubMed ID: 23786539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease.
    Shehadeh J; Fernandes HB; Zeron Mullins MM; Graham RK; Leavitt BR; Hayden MR; Raymond LA
    Neurobiol Dis; 2006 Feb; 21(2):392-403. PubMed ID: 16165367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease.
    Pouladi MA; Brillaud E; Xie Y; Conforti P; Graham RK; Ehrnhoefer DE; Franciosi S; Zhang W; Poucheret P; Compte E; Maurel JC; Zuccato C; Cattaneo E; Néri C; Hayden MR
    Neurobiol Dis; 2012 Dec; 48(3):282-9. PubMed ID: 22796360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease.
    Simmons DA; Casale M; Alcon B; Pham N; Narayan N; Lynch G
    Glia; 2007 Aug; 55(10):1074-84. PubMed ID: 17551926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.
    Slow EJ; van Raamsdonk J; Rogers D; Coleman SH; Graham RK; Deng Y; Oh R; Bissada N; Hossain SM; Yang YZ; Li XJ; Simpson EM; Gutekunst CA; Leavitt BR; Hayden MR
    Hum Mol Genet; 2003 Jul; 12(13):1555-67. PubMed ID: 12812983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell suspension methodology favors survival and vascularization of fetal striatal grafts in the YAC128 mouse model of Huntington's disease.
    Cisbani G; Saint-Pierre M; Cicchetti F
    Cell Transplant; 2014; 23(10):1267-78. PubMed ID: 23768945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes.
    Petrella LI; Castelhano JM; Ribeiro M; Sereno JV; Gonçalves SI; Laço MN; Hayden MR; Rego AC; Castelo-Branco M
    Hum Mol Genet; 2018 Jun; 27(12):2125-2137. PubMed ID: 29668904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology.
    Drouin-Ouellet J; Sawiak SJ; Cisbani G; Lagacé M; Kuan WL; Saint-Pierre M; Dury RJ; Alata W; St-Amour I; Mason SL; Calon F; Lacroix S; Gowland PA; Francis ST; Barker RA; Cicchetti F
    Ann Neurol; 2015 Aug; 78(2):160-77. PubMed ID: 25866151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
    Wade A; Jacobs P; Morton AJ
    Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease.
    Southwell AL; Franciosi S; Villanueva EB; Xie Y; Winter LA; Veeraraghavan J; Jonason A; Felczak B; Zhang W; Kovalik V; Waltl S; Hall G; Pouladi MA; Smith ES; Bowers WJ; Zauderer M; Hayden MR
    Neurobiol Dis; 2015 Apr; 76():46-56. PubMed ID: 25662335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease.
    Carroll JB; Lerch JP; Franciosi S; Spreeuw A; Bissada N; Henkelman RM; Hayden MR
    Neurobiol Dis; 2011 Jul; 43(1):257-65. PubMed ID: 21458571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice.
    Dau A; Gladding CM; Sepers MD; Raymond LA
    Neurobiol Dis; 2014 Feb; 62():533-42. PubMed ID: 24269729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C57BL/6 Background Attenuates mHTT Toxicity in the Striatum of YAC128 Mice.
    Back MK; Kurzawa J; Ruggieri S; von Engelhardt J
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.